N/A N=167 Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)
Temporal Lobe Epilepsy
Primary: Incidence of Qualifying Adverse Events — 7.9 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5 Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation
Epilepsy, Temporal Lobe
Primary: Self-reported Seizure Frequency — 6.4 seizure days per 4 weeks
N/A N=3 Low Frequency Electrical Stimulation of the Fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)
Mesial Temporal Lobe Epilepsy
Primary: Safety and Tolerability of Low Frequency Stimulation of the Fornix With Regards to Memory Function — 0; 0 Participants
N/A N=22 Transcranial Magnetic Stimulation for BECTS
Benign Epilepsy With Centrotemporal Spikes · Language Problems · Learning Disorders
Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04
Phase 2 N=50 External Trigeminal Nerve Stimulation for Epilepsy
Epilepsy · Seizure Disorders
Primary: 50% Responder Rate — 40.5; 15.6 percentage of participants
N/A N=11 Treatment of Difficult to Control Focal Epilepsy With Repetitive Transcranial Magnetic Stimulation (rTMS)
Epilepsies, Partial
Primary: 50% Responder Rate After Active rTMS Treatment Compared With Placebo Treatment — 0; 0; 0; 0 participants
N/A N=15 Low Frequency TMS for Depression in Epilepsy
Epilepsy · Depressions, Refractory
Primary: Change in Seizure Frequency Expressed as the Average Number of Seizures Experienced by All Participants and Recorded at Specified Time Points Throughout the Study…
N/A N=60 Neocortical Epilepsies - Do They Progress?
Epilepsy
Primary: Functional Connectivity
Phase 3 N=109 SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy
Epilepsy
Primary: Primary Analysis: Change in Seizure Rate — -40.4; -14.5 Percentage change from baseline — p=0.0017
Phase 2 N=126 Levetiracetam to Prevent Post-Traumatic Epilepsy
Epilepsy · Post-traumatic Epilepsy
Primary: Post-Traumatic Epilepsy — 6; 8 participants
Phase 4 N=22 Transcranial Direct Current Stimulation, Treatment of Childhood Drug-Resistant Lennox-Gastaut Syndrome, A Pilot Study
Lennox-Gastaut Syndrome
Primary: Number of Seizure After Treatment by tDCS — 80.67; 93.43; 35.53; 93.14 seizures — p=<0.05
N/A N=29 Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?
Epilepsy
Primary: The Change Scores in Memory Measures From Baseline to Post-treatment/Placebo Will be Compared Between the Memantine Treatment and Placebo Groups. — 1.00; 1.78; 4.38…
Phase 4 N=60 ECT Pulse Amplitude and Medial Temporal Lobe Engagement
Major Depressive Disorder
Primary: Depression Severity — 22.5; 12.0; 14.1 score on a scale — p=0.04
Phase 2 N=7 Thalidomide Low Threshold in Epilepsy
Refractory Epilepsy
Primary: Change From Baseline in the Mean Number of Daily Seizures at 1 Year. — 9 Number of Seizures — p=<0.02
N/A N=3 Transmagnetic Stimulation Pilot in Primary Progressive Aphasia
Primary Progressive Aphasia
Primary: Connectivity Measures of the Left TGd, 55b, and STV Parcellations at Baseline and Post-treatment — -.06; .03; -.01 correlation
N/A N=44 Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)
Epilepsy · Schizophrenia · Schizoaffective Disorder
Primary: Change in Montgomery Asberg Depression Rating Scale (MADRS) — 16.75; 22.94; 11.21; 21.81 score on a scale — p=0.036
N/A N=10 Pediatric Language and Memory Mapping in Refractory Epilepsy Using Magnetoencephalography
Epilepsy
Primary: Completed MEG — 1 participants
N/A N=31 Cognitive Effects of Treatment of Interictal Discharges
Epilepsy
Primary: Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment — -28.8; .54 IEDs/hour — p=>0.05
Phase 3 N=251 A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)
Epilepsy · Generalized Tonic-Clonic Seizures
Primary: Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation…
Phase 2 N=84 Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
Tuberous Sclerosis Complex
Primary: Cognitive Assessment Scores and Developmental Impact — 83.9; 80.9; 97.3; 85.0 score on a scale — p=0.8681
Phase 2 N=18 Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies
Developmental and/or Epileptic Encephalopathies
Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE), as Reported by the Participants or Participant's Caregivers or Observed by the…
Phase 2 N=15 A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
Epilepsy · Tuberous Sclerosis Complex · Focal Cortical Dysplasia
Primary: Number of Patients With Adverse Events — 0; 0 Participants
Phase 3 N=67 Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy
Epilepsy
Primary: Number of Participants Who Were Seizure Free in the Maintenance Phase (Across Seizure Types and by Seizure Type Within 6 Months Prior to the Start of the Study) — 28…
N/A N=17 Arterial Spin Labeling MRI Focal Abnormalities in Refractory Epilepsy
Focal Epilepsy
Primary: Intensity of the MRI Signal in the Left Temporal Precentral Zone — 1.06; 1.04 ratio
Phase 2 N=20 Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
Epilepsy · Tuberous Sclerosis Complex
Primary: Reduction in Seizure Frequency — 60 percentage
Phase 3 N=122 Lamotrigine Extended-Release In Elderly Patients With Epilepsy
Epilepsy
Primary: Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event — 22; 112 participants
N/A N=93 Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors
Brain Tumor Related Epilepsy (BTRE)
Primary: Percentage of Patients With Response at the End of the 6-month Observation Period — 76.7 percentage of patients
Phase 3 N=478 Established Status Epilepticus Treatment Trial
Benzodiazepine Refractory Status Epilepticus
Primary: Number of Participants With Clinical Cessation of Status Epilepticus - Intention to Treat — 53; 56; 68 Participants
N/A N=10 Treating Non-epileptic Seizures Using Magnetic Brain Stimulation
Nonepileptic Seizures
Primary: Number of Weekly Psychogenic Non-epileptic Seizure-events — 6.9; 5.3 events
N/A N=12 Improving Hallucinations by Targeting the rSTS With tES
Hallucinations, Auditory · Psychosis
Primary: Positive and Negative Syndrome Scale (PANSS) — 60.5; 60; 56; 63 score on a scale